ConductScience.org, home

Paper36498473

Pharmacokinetics, Pharmacodynamics, and Dosing Considerations of Novel β-Lactams and β-Lactam/β-Lactamase Inhibitors in Critically Ill Adult Patients: Focus on Obesity, Augmented Renal Clearance, Renal Replacement Therapies, and Extracorporeal Membrane Oxygenation.

Bakdach D and 5 others. J Clin Med, 2022. Cited by 31 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Pharmacokinetics, Pharmacodynamics, and Dosing Considerations of Novel β-Lactams and β-Lactam/β-Lactamase Inhibitors in Critically Ill Adult Patients: Focus on Obesity, Augmented Renal Clearance, Renal Replacement Therapies, and Extracorporeal Membrane Oxygenation. Papers, record 36498473. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36498473

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Pharmacokinetics, Pharmacodynamics, and Dosing Considerations of Novel β-Lactams and β-Lactam/β-Lactamase Inhibitors in Critically Ill Adult Patients: Focus on Obesity, Augmented Renal Clearance, Renal Replacement Therapies, and Extracorporeal Membrane Oxygenation.
PubMed
Journal
J Clin Med
PubMed
Year
2022
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
31
iCite
Relative citation ratio, by iCite
3.67
iCite
Revised in PubMed
2024-09-08
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bakdach DDanahttps://orcid.org/0000-0001-7173-2776
2Elajez RReemhttps://orcid.org/0000-0001-7824-3203
3Bakdach ARAbdul Rahman
4Awaisu AAhmedhttps://orcid.org/0000-0002-9029-8925
5De Pascale GGennaro
6Ait Hssain AAlihttps://orcid.org/0000-0002-7764-5793

Source PubMed

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References96

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133,292,582The higher the better? Defining the optimal beta-lactam target for critically ill patients to reach infection resolution and improve outcome.J Intensive Care2020https://conductscience.org/library/papers/33292582PubMed
210,990,106Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score.Intensive Care Med2000https://conductscience.org/library/papers/10990106PubMed
321,333,028Antibiotic dosing in the 'at risk' critically ill patient: Linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients.BMC Anesthesiol2011https://conductscience.org/library/papers/21333028PubMed
419,397,464Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis.Pharmacotherapy2009https://conductscience.org/library/papers/19397464PubMed
523,642,005Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?Crit Care2013https://conductscience.org/library/papers/23642005PubMed
627,451,086Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration.Int J Antimicrob Agents2016https://conductscience.org/library/papers/27451086PubMed
730,626,244Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens.Expert Opin Drug Metab Toxicol2019https://conductscience.org/library/papers/30626244PubMed
828,571,493Optimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?Expert Rev Anti Infect Ther2017https://conductscience.org/library/papers/28571493PubMed
931,358,583Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction.Antimicrob Agents Chemother2019https://conductscience.org/library/papers/31358583PubMed
1024,768,475Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.Lancet Infect Dis2014https://conductscience.org/library/papers/24768475PubMed
1128,158,470Determining β-lactam exposure threshold to suppress resistance development in Gram-negative bacteria.J Antimicrob Chemother2017https://conductscience.org/library/papers/28158470PubMed
1216,355,321The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs.Clin Infect Dis2006https://conductscience.org/library/papers/16355321PubMed
1334,224,115Pharmacokinetics of Commonly Used Antimicrobials in Critically Ill Adults During Extracorporeal Membrane Oxygenation: A Systematic Review.Drugs2021https://conductscience.org/library/papers/34224115PubMed
1431,325,141What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review.Clin Pharmacokinet2019https://conductscience.org/library/papers/31325141PubMed
1534,034,594Oxygenator impact on meropenem/vaborbactam in extracorporeal membrane oxygenation circuits.Perfusion2022https://conductscience.org/library/papers/34034594PubMed
1627,012,450Ceftolozane/Tazobactam Pharmacokinetics in a Critically Ill Adult Receiving Continuous Renal Replacement Therapy.Pharmacotherapy2016https://conductscience.org/library/papers/27012450PubMed
1715,656,698Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration.Clin Pharmacokinet2005https://conductscience.org/library/papers/15656698PubMed
1834,250,190Cefiderocol Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemodiafiltration.Open Forum Infect Dis2021https://conductscience.org/library/papers/34250190PubMed
1920,862,453Determinants of drug absorption in different ECMO circuits.Intensive Care Med2010https://conductscience.org/library/papers/20862453PubMed
2023,683,557Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy.J Crit Care2013https://conductscience.org/library/papers/23683557PubMed

See all 96 references

Cited by24

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 31 citations.

PMIDTitleJournalYearIn PapersSource
42,802,803
Model-Informed Ceftazidime-Avibactam Dosing Stratified by Renal Function and Renal Replacement Therapy Status in Critically Ill Patients: A Prospective Population Pharmacokinetic and Monte Carlo Simulation Study.
Drug Des Devel Ther2026https://conductscience.org/library/papers/42802803PubMed
42,781,062Prediction of Meropenem Target Attainment in Critically Ill Patients Using Routine Clinical Data from a Single Center: A Machine Learning Approach.Infect Drug Resist2026https://conductscience.org/library/papers/42781062PubMed
42,353,742Real-World Evidence: Cefiderocol Therapeutic Drug Monitoring in Critically Ill, Obese Patients with Klebsiella pneumoniae Infections.Antibiotics (Basel)2026https://conductscience.org/library/papers/42353742PubMed
41,892,463Prescribing Patterns and Clinical Outcomes of Ceftolozane/Tazobactam by Renal Function and Body Mass Index: A SPECTRA Real-World Multi-Country Analysis.Antibiotics (Basel)2026https://conductscience.org/library/papers/41892463PubMed
41,859,700Antimicrobial Pharmacokinetic and Pharmacodynamic Considerations in Special Populations: A Call to Action.Open Forum Infect Dis2026https://conductscience.org/library/papers/41859700PubMed
41,283,612Optimizing Drug Therapy in ECMO-Supported Critically Ill Adults: A Narrative Review and Clinical Guide.Pharmacy (Basel)2025https://conductscience.org/library/papers/41283612PubMed
41,239,168PK/PD study of ceftazidime/avibactam in patients with severe intra-abdominal infections treated by continuous veno-venous hemofiltration.Eur J Clin Microbiol Infect Dis2026https://conductscience.org/library/papers/41239168PubMed
40,852,616
Continuous infusion versus intermittent dosing of ceftazidime/avibactam in critically ill patients with Klebsiella pneumoniae OXA-48 or Pseudomonas aeruginosa infections: a single-center randomized open-label trial (ZAVICONT). Rationale and design.
Front Pharmacol2025https://conductscience.org/library/papers/40852616PubMed
39,596,718Impact of Extracorporeal Membrane Oxygenation (ECMO) on Serum Concentrations of Cefepime.Antibiotics (Basel)2024https://conductscience.org/library/papers/39596718PubMed
39,530,161Dynamic distribution of systemically administered antibiotics in orthopeadically relevant target tissues and settings.APMIS2024https://conductscience.org/library/papers/39530161PubMed
39,425,201Cefiderocol pharmacokinetics in critically ill patients undergoing ECMO support.Crit Care2024https://conductscience.org/library/papers/39425201PubMed
39,384,682In vivo development of resistance to novel β-lactam/β-lactamase inhibitor combinations in KPC-producing Klebsiella pneumoniae infections: a case series.Eur J Clin Microbiol Infect Dis2024https://conductscience.org/library/papers/39384682PubMed
39,061,311Novel Antibiotics for Gram-Negative Nosocomial Pneumonia.Antibiotics (Basel)2024https://conductscience.org/library/papers/39061311PubMed
39,035,618Understanding antimicrobial pharmacokinetics in critically ill patients to optimize antimicrobial therapy: A narrative review.J Intensive Med2024https://conductscience.org/library/papers/39035618PubMed
39,005,857Adequacy of the Dosing and Infusion Time of Ceftazidime/Avibactam for the Treatment of Gram-Negative Bacterial Infections: A PK/PD Simulation Study.Infect Drug Resist2024https://conductscience.org/library/papers/39005857PubMed
38,786,181Role of Cefiderocol in Multidrug-Resistant Gram-Negative Central Nervous System Infections: Real Life Experience and State-of-the-Art.Antibiotics (Basel)2024https://conductscience.org/library/papers/38786181PubMed
38,526,051Updated antimicrobial dosing recommendations for obese patients.Antimicrob Agents Chemother2024https://conductscience.org/library/papers/38526051PubMed
38,433,781Model-Informed Precision Dosing of Imipenem in an Obese Adolescent Patient with Augmented Renal Clearance and History of Schizophrenia.Infect Drug Resist2024https://conductscience.org/library/papers/38433781PubMed
38,099,629Meropenem extraction by ex vivo extracorporeal life support circuits.J Extra Corpor Technol2023https://conductscience.org/library/papers/38099629PubMed
37,720,698Weighing the Odds: Novel β-Lactam/β-Lactamase Inhibitor Use in Hospital-Acquired and Ventilator-Associated Pseudomonas aeruginosa Pneumonia for Patients Who Are Morbidly Obese.Open Forum Infect Dis2023https://conductscience.org/library/papers/37720698PubMed

See all 24 cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
CRCL261,727PubTator's text mininghttps://conductscience.org/library/genes/261727

Source NCBI Gene

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36498473

GET https://conductscience.org/api/papers/v1/36498473/references?page=2